quetmolimab: Clinical Trials

7 completed, 1 terminated, 1 withdrawn. 6 Phase 2, 5 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	6	Completed 5, Terminated 1
Phase 1	5	Completed 4, Withdrawn 1

Follow quetmolimab: new trials by email Literature Review of quetmolimab trials Research Report on quetmolimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of E6011 in Participants With Active Crohn's Disease E6011, Placebo - Crohn's Disease	Phase 2	Completed	EA Pharma Co., Ltd.	25	2019-04-25	2025-04-02
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid E6011, Placebo - Primary Biliary Cholangitis	Phase 2	Terminated	EA Pharma Co., Ltd.	29	2017-05-29	2019-01-04
A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics E6011, Placebo - Rheumatoid Arthritis	Phase 2	Completed	Eisai Co., Ltd.	66	2016-11-26	2021-08-23
A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate E6011, Placebo - Rheumatoid Arthritis	Phase 2	Completed	Eisai Co., Ltd.	273	2016-10-20	2021-06-21
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease E6011, Placebo - Crohn's Disease	Phase 1	Withdrawn	Eisai Inc.		2014-12-01	2015-11-05
A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis E6011 - Arthritis, Rheumatoid	Phase 1 / Phase 2	Completed	Eisai Co., Ltd.	53	2014-05-26	2020-08-13
A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease E6011 2 mg/kg, E6011 5 mg/kg, E6011 10 mg/kg - Crohn's Disease	Phase 1 / Phase 2	Completed	EA Pharma Co., Ltd.	28	2014-04-05	2023-01-30
A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects E6011, Placebo - Healthy	Phase 1	Completed	Eisai Co., Ltd.	32	2013-09-01	2014-10-22
A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001) E6011, E6011 Matching Placebo - Healthy Male Volunteers	Phase 1	Completed	Eisai Co., Ltd.	64	2012-08-01	2014-02-14

Conditions studied

Arthritis, Rheumatoid (3)  ·  Crohn Disease (3)  ·  Gastroenteritis (1)  ·  Inflammatory Bowel Diseases (1)  ·  Liver Cirrhosis, Biliary (1)

Sponsors

Eisai Co., Ltd. (5)  ·  EA Pharma Co., Ltd. (3)  ·  Eisai Inc. (1)

Countries

Japan (8)  ·  Czechia (1)  ·  Hungary (1)  ·  Poland (1)  ·  Russia (1)

Top investigators

Kiyoshi Oketani (1)

Results publications

PMID 28681650, PMID 33038062, PMID 33599356

NIH funding

2018 (1)